The present report reviews the revised 2018 FDA guidance for early AD, with an emphasis on meaningfulness of clinical outcome assessments (COAs). A radical shift is evident in the importance given to establishing the meaningfulness of COAs in the 2018… Continue Reading →

 Our objective was to significantly facilitate recruitment into AD clinical trials by providing resources and education to patients, their treating physicians, and caregivers in the community. Park, C. Kouhanim, S. Lee, Z. Mendoza, K. Patrick, L. Gertsik, C. Aguilar, D…. Continue Reading →

There is an urgent need to develop reliable and sensitive bloodbased biomarkers of Alzheimer’s disease (AD) that can be used for screening and to increase the efficiency of clinical trials. The European Union-North American Clinical Trials in Alzheimer’s Disease Task… Continue Reading →